409 related articles for article (PubMed ID: 23150653)
1. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I
Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
Olson FJ; Thurison T; Ryndel M; Høyer-Hansen G; Fagerberg B
Clin Biochem; 2010 Jan; 43(1-2):124-30. PubMed ID: 19822140
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis.
Svensson PA; Olson FJ; Hägg DA; Ryndel M; Wiklund O; Karlström L; Hulthe J; Carlsson LM; Fagerberg B
Int J Mol Med; 2008 Oct; 22(4):459-64. PubMed ID: 18813852
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
5. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
[TBL] [Abstract][Full Text] [Related]
6. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation.
Gonçalves I; Edsfeldt A; Ko NY; Grufman H; Berg K; Björkbacka H; Nitulescu M; Persson A; Nilsson M; Prehn C; Adamski J; Nilsson J
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1505-12. PubMed ID: 22499993
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
[TBL] [Abstract][Full Text] [Related]
10. Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
Asciutto G; Edsfeldt A; Dias NV; Nilsson J; Prehn C; Adamski J; Gonçalves I
Cardiovasc Pathol; 2013; 22(6):438-43. PubMed ID: 23747086
[TBL] [Abstract][Full Text] [Related]
11. Release of soluble urokinase receptor from vascular cells.
Chavakis T; Willuweit AK; Lupu F; Preissner KT; Kanse SM
Thromb Haemost; 2001 Aug; 86(2):686-93. PubMed ID: 11522023
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
[TBL] [Abstract][Full Text] [Related]
13. CRP and suPAR are differently related to anthropometry and subclinical organ damage.
Lyngbæk S; Sehestedt T; Marott JL; Hansen TW; Olsen MH; Andersen O; Linneberg A; Madsbad S; Haugaard SB; Eugen-Olsen J; Jeppesen J
Int J Cardiol; 2013 Aug; 167(3):781-5. PubMed ID: 22459389
[TBL] [Abstract][Full Text] [Related]
14. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
15. Human Carotid Plaques With High Levels of Interleukin-16 Are Associated With Reduced Risk for Cardiovascular Events.
Grönberg C; Bengtsson E; Fredrikson GN; Nitulescu M; Asciutto G; Persson A; Andersson L; Nilsson J; Gonçalves I; Björkbacka H
Stroke; 2015 Oct; 46(10):2748-54. PubMed ID: 26330445
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
[TBL] [Abstract][Full Text] [Related]
18. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Sloand EM; Pfannes L; Scheinberg P; More K; Wu CO; Horne M; Young NS
Exp Hematol; 2008 Dec; 36(12):1616-24. PubMed ID: 18954937
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin induces soluble urokinase-type plasminogen activator receptor production and release.
Vaschetto R; Navalesi P; Clemente N; Boggio E; Valsecchi S; Olivieri C; Soluri MF; Kroumova V; Fonio P; Dinatale C; Borrè S; Fortina G; Umberto D; Della Corte F; Chiocchetti A
Minerva Anestesiol; 2015 Feb; 81(2):157-65. PubMed ID: 24994498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
